• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603139.SS
Share

Shaanxi Kanghui Pharmaceutical Co., Ltd. Stocks

CN¥ 39.89Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 601.99M

CN¥ 39.89
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shaanxi Kanghui Pharmaceutical Co., Ltd. is a Chinese company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its comprehensive portfolio includes medications targeting numerous therapeutic areas, such as women's health, orthopedic conditions, dermatological issues, diabetes, respiratory ailments, urinary system disorders, cardiovascular and cerebrovascular diseases, gastrointestinal problems, and hepatobiliary complaints. These drugs are available in various dosage forms, including tablets, capsules, granules, mixtures, teas, plasters, ointments, liniments, lotions, and tinctures. The company's headquarters are situated in Xianyang, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 12:20

DeepSeek Founder Is Now the Richest AI Model Developer — Bloomberg

14.07.2026 11:10

Oil prices soared to a one-month high following new attacks by the U.S. and Iran in the Strait of Hormuz

14.07.2026 10:44

Intraday volatility: SK Hynix shares rebounded after a 9% plunge

14.07.2026 10:38

Morning Highlights: Oil Prices Rise Amid Strikes on Iran; Nvidia Tightens Export Controls

14.07.2026 09:30

Sam Altman "took the scam to a whole new level": Musk comments on Apple's lawsuit against OpenAI

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026